Document is current
Any future updates will be listed below
-
Authors
Johansson, Camilla https://orcid.org/0000-0002-2685-5715
Johansson, Martin
Kasi, Phanindra Babu
Larsson, Mårten https://orcid.org/0000-0002-7855-9539
Jakobsson, Per-Johan https://orcid.org/0000-0001-7665-9715
Göransson, Ulf
Carreras Puigvert, Jordi
Spjuth, Ola https://orcid.org/0000-0002-8083-2864
Jansson, Erik T https://orcid.org/0000-0002-0675-3412
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2025-03970,2024-04576,2024-03566)
Vetenskapsrådet (2021-00179)
Cancerfonden (22 2412 Pj 03 H)
EC HORIZON EUROPE Framework Programme (101057442)
Svenska Forskningsrådet Formas (2022-00940)
Carl Tryggers Stiftelse för Vetenskaplig Forskning
Magnus Bergvalls Stiftelse
Chemical Biology Consortium Sweden
Science for Life Laboratory
Guangdong Provincial Hospital of Chinese Medicine
- License Information
-
More Information
Article History
Received: 8 July 2025
Revised: 17 April 2026
Accepted: 21 April 2026
First Online: 15 May 2026
Disclosure and competing interests statement
: JCP and OS declare ownership in Phenaros Pharmaceuticals.
